Given Imaging Partners with Fujinon to Distribute PillCam(R) Capsule Endoscopy in China

Given Imaging Partners with Fujinon to Distribute PillCam(R) Capsule Endoscopy in China

October 27, 2007

- Company to Display the PillCam Platform at China
International Medical Equipment Fair -

    YOQNEAM, Israel and SAITAMA CITY, Japan, Oct. 27
/Xinhua-PRNewswire/ --

    Given Imaging Ltd. (Nasdaq: GIVN), the global leader in
capsule endoscopy, and Fujinon Corporation, a global leader
in optical technologies and endoscopic equipment, today
announced that as part of their strategic cooperation
announced earlier this year Fujinon will serve as Given's
master distributor for PillCam capsule endoscopy in China.
Financial details were not disclosed. 

    "China is the only country in this region where we
have regulatory approval for both PillCam(R) SB and
PillCam(R) ESO and it was important that we have a strong
partner to deliver our products to physicians," said
Kazem Samandari, Senior Vice President, Asia Pacific/Japan
Region of Given Imaging. "We look forward to expanding
our collaboration with Fujinon on this important initiative
for us in Asia-Pacific." 

    Capsule endoscopy for the small bowel was cleared in
China in 2002 and capsule endoscopy for the esophagus was
cleared in 2007. Fujinon has been operating in China since
1996 and has 4 offices and employs 200 people. 

    Given will be demonstrating the PillCam Platform at the
China International Medical Equipment Fair, the largest
medical device show in China and Asia,  October 24 to 27 at
the New International Convention and Exposition Center in
Chengdu, China. For more information visit
http://en.cmef.com.cn/tabid/349/Default.aspx. 

    About Given Imaging Ltd. 

    Given Imaging is redefining gastrointestinal diagnosis
by developing, producing and marketing innovative,
patient-friendly products for detecting gastrointestinal
disorders. The company's technology platform is the
PillCam(R) Platform, featuring the PillCam video capsule, a
disposable, miniature video camera contained in a capsule,
which is ingested by the patient, a sensor array, data
recorder and RAPID(R) software. Given Imaging has a number
of commercially available capsules: the PillCam SB video
capsule to visualize the entire small intestine which is
currently marketed in the United States and in more than 60
other countries; the PillCam ESO video capsule to visualize
the esophagus; the Agile(TM) patency capsule to determine
the free passage of the PillCam capsule in the GI tract;
and the PillCam COLON video capsule to visualize the colon
that has been cleared for marketing in the European Union
and is pending clearance with the United States Food and
Drug Administration.  More than 600,000 patients worldwide
have benefited from the PillCam capsule endoscopy
procedure. Given Imaging's headquarters, manufacturing and
R&D facilities are located in Yoqneam, Israel. It has
operating subsidiary companies in the United States,
Germany, France, Japan and Australia.  For more
information, visit http://www.givenimaging.com. 

    About Fujinon 

    Fujinon has continually developed as an optical
equipment manufacturer of Fujifilm Group. The company has
developed numerous products compatible with
high-performance and high-quality images using the
established optical techniques and provided them to the
whole world. In the broadcast fields, the company developed
lens compatible with Hi-Vision early and got various lineup
including the 101x lens which is the highest quality zoom
lens in the world, to have more than 50% of the worldwide
market share. Regarding the lens unit for a mobile phone
with camera function getting popular in the market, the
company leads the world with high-resolution, compact lens
unit using aspherical lenses. 

    In the fields of endoscopes, the company has developed
continuously various innovative products promoted the
expansion of business by introducing the products such as
Double-Balloon Endoscope System, which make the examination
and treatment in whole small intestine possible, endoscopic
diagnostic imaging support functions FICE, and trans-nasal
gastroscope which is prevailing in Japan and Asia for the
examination with less pain to be inserted through the nose.


    Endoscope business of the company maintains two-digit
growth every year, and aims at further expansion and growth
in the fields of gastroenterological endoscopy. 

    This press release contains forward-looking statements
within the meaning of the "safe harbor"
provisions of the U.S. Private Securities Litigation Reform
Act of 1995. These forward-looking statements include, but
are not limited to, projections about our business and our
future revenues, expenses and profitability.
Forward-looking statements may be, but are not necessarily,
identified by the use of forward-looking terminology such as
"may," "anticipates,"
"estimates," "expects,"
"intends," "plans,"
"believes," and words and terms of similar
substance. Forward-looking statements involve known and
unknown risks, uncertainties and other factors which may
cause the actual events, results, performance,
circumstances or achievements of the Company to be
materially different from any future events, results,
performance, circumstances or achievements expressed or
implied by such forward-looking statements. Factors that
could cause actual events, results, performance,
circumstances or achievements to differ from such
forward-looking statements include, but are not limited to,
the following: (1) satisfactory results of clinical trials
with PillCam Colon (2) our ability to receive regulatory
clearance or approval to market our products or changes in
regulatory environment, (3) our success in implementing our
sales, marketing and manufacturing plans, (4) protection and
validity of patents and other intellectual property rights,
(5) the impact of currency exchange rates, (6) the effect
of competition by other companies, (7) the outcome of
future litigation, including patent litigation with Olympus
Corporation, (8) the reimbursement policies for our product
from healthcare payors, (9) quarterly variations in
operating results, (10) the possibility of armed conflict
or civil or military unrest in Israel, and (11) other risks
and factors disclosed in our filings with the U.S.
Securities and Exchange Commission, including, but not
limited to, risks and factors identified under such
headings as "Risk Factors," "Cautionary
Language Regarding Forward-Looking Statements" and
"Operating Results and Financial Review and
Prospects" in the Company's Annual Report on Form 20-F
for the year ended December 31, 2006. You are cautioned not
to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release. Except for the Company's ongoing obligations to
disclose material information under the applicable
securities laws, it undertakes no obligation to release
publicly any revisions to any forward-looking statements,
to report events or to report the occurrence of
unanticipated events. 


    For further information contact:

    Fern Lazar/David Carey
    Lazar Partners Ltd.
    Phone: [phone] 
    Email: [e-mail] /
[e-mail]